2024
Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review
Nasioudis D, Pashankar F. Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review. International Journal Of Gynecological Cancer 2024, 34: 1454-1460. PMID: 38991656, DOI: 10.1136/ijgc-2023-005052.Peer-Reviewed Original ResearchMalignant ovarian germ cell tumorsOvarian germ cell tumorsGerm cell tumorsCell tumorsHigh-dose chemotherapy protocolsPlatinum-resistant diseasePlatinum-sensitive diseaseSecondary cytoreductive surgeryPlatinum-based chemotherapyStandard dose chemotherapyCytoreductive surgeryDose chemotherapyTumor relapseOptimal resectionChemotherapy protocolsGenomic alterationsSpecialized centersTumorTherapeutic approachesSensitive diseasePatientsChemotherapyNarrative reviewOptimal timingDisease
2022
Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group
Dicken B, Billmire D, Rich B, Hazard F, Nuño M, Krailo M, Fallahazad N, Pashankar F, Shaikh F, Frazier A. Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group. Gynecologic Oncology 2022, 166: 476-480. PMID: 35750503, PMCID: PMC9514449, DOI: 10.1016/j.ygyno.2022.06.013.Peer-Reviewed Original ResearchConceptsIntra-operative frozen sectionOvarian germ cell tumorsGerm cell tumorsMalignant ovarian germ cell tumorsIntra-operative frozen section diagnosisFrozen section diagnosisCentral pathology reviewCell tumorsSurgical stagingAdolescent patientsFinal diagnosisFinal paraffin section diagnosisSection diagnosisFrozen sectionsParaffin section diagnosisOncology GroupPathology reviewCentral reviewOvarian germ cell malignanciesNonseminomatous germ cell tumorsGerm cell tumor componentsConfirmation of malignancyGerm cell malignanciesRecords of patientsChildren's Oncology Group
2020
Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology
Billmire D, Dicken B, Rescorla F, Ross J, Piao J, Huang L, Krailo M, Pashankar F, Frazier L, Group C. Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology. Journal Of Pediatric And Adolescent Gynecology 2020, 34: 383-386. PMID: 33316416, PMCID: PMC8096645, DOI: 10.1016/j.jpag.2020.11.014.Peer-Reviewed Original ResearchConceptsMalignant ovarian germ cell tumorsMalignant germ cell tumorsGerm cell tumorsOvarian germ cell tumorsCell tumorsOncology GroupMalignant histologyImaging appearancesExtracranial malignant germ cell tumorsNonseminomatous malignant germ cell tumorsOvarian malignant germ cell tumorsSolid appearanceComplete surgical stagingElement of teratomaPediatric ovarian neoplasmsPreoperative serum markersChildren's Oncology GroupPrimary ovarian tumorsYolk sac tumorYears of ageAssociated teratomaTeratoma elementsSurgical stagingMixed histologyMulticenter trial
2018
Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecologic Oncology 2018, 150: 253-260. PMID: 29884437, DOI: 10.1016/j.ygyno.2018.05.025.Peer-Reviewed Original ResearchConceptsCisplatin-based chemotherapyClinical trial organizationsGerm cell tumorsFive-year event-free survivalMalignant ovarian germ cell tumorsOvarian germ cell tumorsAge groupsCarboplatin-based chemotherapyTreatment-related toxicityEvent-free survivalEligible patientsExcellent OSMetastatic diseaseOverall survivalClinical outcomesFrontline treatmentSurvival outcomesMean agePeak incidenceCell tumorsDysgerminomaChemotherapyPatientsTrials OrganizationCarboplatinOvarian Yolk Sac Tumors; Does Age Matter?
Conter C, Xia C, Gershenson D, Hurteau J, Covens A, Pashankar F, Krailo M, Billmire D, Patte C, Fresneau B, Shaikh F, Stoneham S, Nicholson J, Murray M, Frazier AL. Ovarian Yolk Sac Tumors; Does Age Matter? International Journal Of Gynecological Cancer 2018, 28: 77-84. PMID: 29194189, DOI: 10.1097/igc.0000000000001149.Peer-Reviewed Original ResearchConceptsOvarian yolk sac tumorEvent-free survivalYolk sac tumorOverall survivalSac tumorClinical trialsOvarian germ cell tumorsPreoperative alpha-fetoprotein levelAge cut pointStage IV diseaseAdverse prognostic factorPlatinum-based chemotherapyAlpha-fetoprotein levelsCut pointsGerm cell tumorsPediatric clinical trialsRisk of eventsOptimal cut pointJoint pediatricChemosensitive tumorsChemotherapeutic regimenPrognostic impactPrognostic factorsAdult trialsGynecologic oncologists
2017
Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study
Dicken BJ, Billmire DF, Krailo M, Xia C, Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Rescorla FJ, Egler RA, Ross JH, Rodriguez‐Galindo C, Frazier AL. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study. Pediatric Blood & Cancer 2017, 65 PMID: 29286555, PMCID: PMC6219870, DOI: 10.1002/pbc.26913.Peer-Reviewed Original ResearchConceptsOvarian germ cell tumorsMalignant ovarian germ cell tumorsGerm cell tumorsEvent-free survivalNon-GD patientsOverall survivalGonadal dysgenesisMalignant germ cell tumorsAggressive chemotherapy regimenHigh-risk groupNondysgerminomatous tumorsChemotherapy regimenPure dysgerminomaPediatric patientsSac tumorBilateral gonadectomyCell tumorsWorse outcomesEmbryonal carcinomaPatientsStreak ovariesDysgenetic gonadsTumorsY chromosome materialGonadoblastomaGerm Cell Tumors of the Ovary
Matei D, Frazier A, Hurteau J, Pashankar F. Germ Cell Tumors of the Ovary. 2017, 518-532. DOI: 10.1002/9781119196235.ch35.Peer-Reviewed Original ResearchGerm cell tumorsOvarian germ cell tumorsCell tumorsNondysgerminomatous germ cell tumorsPrimitive germ cell tumorsMixed germ cell tumorCornerstone of treatmentYolk sac tumorPrinciples of diagnosisLong-term toxicityQuality of lifeCurrent multidisciplinary approachLonger life expectancyNongestational choriocarcinomaHistological typeSac tumorRare tumorEmbryonal carcinomaMost womenTumorsYoung womenLife expectancyMultidisciplinary approachWomenTreatment
2014
Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group
Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL. Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group. Journal Of Clinical Oncology 2014, 32: 465-470. PMID: 24395845, PMCID: PMC4876316, DOI: 10.1200/jco.2013.51.1006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlpha-FetoproteinsAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinDisease-Free SurvivalEtoposideFemaleHumansInfantInfant, NewbornKaplan-Meier EstimateNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsRadiographyRisk FactorsSalvage TherapyTime FactorsTreatment OutcomeConceptsMalignant ovarian germ cell tumorsStage I malignant ovarian germ cell tumorsOvarian germ cell tumorsEvent-free survivalGerm cell tumorsOverall survivalAlpha-fetoproteinRecurrent diseaseOncology GroupCell tumorsSuccessful Salvage ChemotherapyTumor marker elevationPercent of patientsKaplan-Meier methodChildren's Oncology GroupSerum tumor markersPredominant histologySalvage chemotherapyInitial surgeryMarker elevationMetastatic diseaseSurgical resectionMedian timeYolk sacTumor markers